Durvalumab, a human monoclonal antibody (MAb), functions as an immune checkpoint inhibitor by blocking the binding of PD-L1 to its receptors, PD-1 and CD80 (B7-1), in order to reactivate tumor-specific T-cell response and enhance antitumor activity. The gene discussed is CD80; the disease is neoplasm.